On May 15, 2024, Jeffrey Church informed Imunon, Inc. of his intent to retire from all positions with the Company, and Mr. Church?s employment with the Company will end, effective June 1, 2024 (the ?Retirement Date?). Mr. Church currently serves as Chief Financial Officer, a position he has held since July 2010. To help ensure a smooth transition of his responsibilities to his successor, Mr. Church and the Company agreed that he will transition to a consulting role with the Company.

As a result of Mr. Church?s retirement, effective June 1, 2024, the Company appointed David Gaiero to serve as the Company?s new Chief Financial Officer under a professional agreement (the ?Agreement?) between the Company and Monomoy Advisors, LLC, a financial advisory services firm (?Monomoy?). Mr. Gaiero will serve as the Company?s principal financial officer and principal accounting officer. Mr. Gaiero, age 46, currently serves as a partner with Monomoy.

Mr. Gaiero has served as Chief Financial Officer of Cyteir Therapeutics, Inc. since January 2023 and previously as their Vice President of Finance from December 2020 until December 2022. Prior to joining Cyteir Therapeutics, Mr. Gaiero served in various roles at Wave Life Sciences from July 2017 to December 2020, most recently serving as Interim Chief Financial Officer and prior to that, serving as Vice President and Corporate Controller. Prior to joining Wave Life Sciences, from September 2015 to July 2017, Mr. Gaiero served as Vice President and Corporate Controller of OvaScience, Inc. Prior to that, Mr. Gaiero held various positions of increasing responsibility and scope in finance and accounting at iRobot Corporation.

Mr. Gaiero began his career in public accounting at PricewaterhouseCoopers LLP. Mr. Gaiero received a B.B.A. in Accounting from the University of Massachusetts, Amherst, and is a Certified Public Accountant in Massachusetts.